Adalimumab Biosimilar Market Size, Share, Growth, and Industry Analysis, By Type (Exemptia, Adalirel, Cipleumab and Others), By Application (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

ADALIMUMAB BIOSIMILAR MARKET OVERVIEW

The global adalimumab biosimilar market size was projected at USD 2.72 Billion in 2026 and is expected to hit USD 4.65 Billion by 2035 with a CAGR of 6.16% during the forecast period from 2026 to 2035.

Adalimumab is a monoclonal antibody that targets tumor necrosis factor alpha (TNF-α), a protein involved in inflammation. It is used to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and psoriasis. A biosimilar is a biological product that is highly similar to an already approved biological product (reference product). In the case of adalimumab biosimilars, these are versions of adalimumab that have been developed to be comparable to the original reference product, which is the brand-name drug Humira®.

Biosimilars undergo a rigorous approval process to demonstrate that they are highly similar to the reference product in terms of safety, efficacy, and quality. The approval of biosimilars provides more treatment options for patients and can contribute to reducing healthcare costs.It's important to note that while biosimilars are highly similar to the reference product, they are not identical. Small differences may exist due to the complexity of biological products. The regulatory authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), carefully evaluate these products before granting approval.

Adalimumab biosimilars are designed to provide therapeutic alternatives to the original adalimumab product, potentially increasing access to treatment and promoting competition in the pharmaceutical market. As of my last knowledge update in January 2022, several biosimilars had received regulatory approval in various regions. However, the specific landscape may have evolved, and it's recommended to check the latest information from regulatory agencies and healthcare providers for the most up-to-date details on biosimilars.

KEY FINDINGS

COVID-19 IMPACT

Clinical Trials and Regulatory Processes to Hinder Market Growth

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic led to disruptions in global supply chains, affecting the production and distribution of pharmaceuticals, including biosimilars. Restrictions on the movement of goods and workforce challenges in some regions may have impacted the availability of adalimumab biosimilars. The pandemic has affected the conduct of clinical trials and regulatory processes. Many clinical trials were delayed or temporarily halted due to safety concerns, logistical issues, and reprioritization of resources toward COVID-19-related activities. Regulatory agencies also faced challenges in reviewing and approving new drugs, including biosimilars. Lockdowns, social distancing measures, and concerns about visiting healthcare facilities may have influenced patient access to treatment. Some patients might have faced challenges in receiving regular injections of adalimumab biosimilars, leading to potential disruptions in their treatment plans.

LATEST TRENDS

Regulatory Approvals to Drive Market Growth

The adalimumab biosimilar market has been expanding, driven by the increasing demand for more cost-effective alternatives to the reference product (Humira®). Competition among biosimilar manufacturers has likely intensified, leading to greater market diversity. More biosimilars have been receiving regulatory approvals in various regions. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have been actively reviewing and approving these products, contributing to a more competitive landscape. Healthcare systems and providers have been increasingly adopting biosimilars as a strategy to manage healthcare costs. The potential for cost savings with biosimilars, while maintaining therapeutic efficacy, has been a key driver of adoption.

• According to the U.S. Food and Drug Administration (FDA), more than 45 biosimilar medicines have been approved in the United States across multiple therapeutic categories, with several approvals specifically targeting inflammatory diseases treated by adalimumab. The European Medicines Agency (EMA) also reported that over 80 biosimilar medicines have received authorization within the European Union, supporting wider availability of lower-cost biologic alternatives. These approvals are accelerating the availability of adalimumab biosimilars used to treat autoimmune disorders such as rheumatoid arthritis, psoriasis, and Crohn’s disease.

• According to the World Health Organization (WHO), autoimmune diseases collectively affect nearly 5% to 8% of the global population, creating significant demand for biologic therapies. The Centers for Disease Control and Prevention (CDC) also notes that rheumatoid arthritis alone affects approximately 1.3 million adults in the United States. As adalimumab is widely prescribed for several chronic inflammatory conditions, the growing patient population requiring long-term biologic therapy is encouraging pharmaceutical companies to introduce biosimilar alternatives.

Download Free Sample to learn more about this report

ADALIMUMAB BIOSIMILAR MARKET SEGMENTATION

By Type

Based on type the global market can be categorized into exemptia, adalirel, cipleumab and others.

Exemptia received regulatory approval in India, and it may be available in other countries where regulatory approvals have been granted. Used in the treatment of various inflammatory conditions, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel diseases.

• Exemptia: Exemptia is a widely recognized adalimumab biosimilar used for the treatment of autoimmune disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. It offers a cost-effective therapeutic alternative to reference biologics while maintaining comparable safety, efficacy, and clinical outcomes.

• Adalirel: Adalirel is a biosimilar formulation of adalimumab designed to provide targeted TNF-alpha inhibition for managing chronic inflammatory conditions. The product is valued for improving treatment accessibility and reducing healthcare costs while maintaining stringent biosimilar regulatory standards.

• Cipleumab: Cipleumab is an adalimumab biosimilar developed to support the treatment of immune-mediated diseases through biologic therapy. It delivers comparable pharmacological performance to originator products while enabling broader patient access through more affordable biologic treatment options.

• Others: The “others” category includes additional adalimumab biosimilars introduced by global pharmaceutical companies to expand therapeutic availability. These products contribute to market competition, price optimization, and wider adoption of biologic therapies in autoimmune disease management.

By Application

Based on application the global market can be categorized into hospital pharmacy, retail pharmacy and online pharmacy.

In many cases, these specialty medications are procured and managed by hospital pharmacies or specialty pharmacies associated with healthcare institutions. Retail and online pharmacies may have a limited role in distributing these types of medications due to their specialized nature and the need for proper handling and administration.

• Hospital Pharmacy: Hospital pharmacies represent a key distribution channel for adalimumab biosimilars, ensuring controlled administration and monitoring for patients undergoing biologic therapy. These facilities support treatment for complex autoimmune conditions through specialist oversight and integrated healthcare infrastructure.

• Retail Pharmacy: Retail pharmacies provide convenient patient access to prescribed adalimumab biosimilars for ongoing treatment and maintenance therapy. This channel supports broader distribution and enhances treatment adherence by enabling patients to obtain biologic medications through community-based pharmacy networks.

• Online Pharmacy: Online pharmacies facilitate digital ordering and home delivery of adalimumab biosimilars, improving accessibility for patients requiring long-term therapy. This distribution model supports healthcare digitization while offering convenience, prescription management, and improved medication availability.

DRIVING FACTORS

Cost Savings and Affordability to Augment the Market

The expiration of patents for the reference product (adalimumab, branded as Humira®) allows for the entry of biosimilar competitors into the market. This creates opportunities for increased competition, potentially leading to lower prices and improved market access. Biosimilars are generally priced lower than their reference biologics. Healthcare systems and payers are motivated to adopt biosimilars as a cost-effective alternative, providing potential savings in healthcare expenditures and improving affordability for patients. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), play a crucial role in the approval and regulation of biosimilars. Favorable regulatory pathways and guidelines for biosimilar approval encourage the development and entry of adalimumab biosimilar market growth.

Growing Acceptance by Healthcare Professionals to Expand the Market

Adalimumab is indicated for the treatment of various chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel diseases. The rising prevalence of these diseases globally contributes to a growing demand for effective and affordable treatments, driving the adoption biosimilars. As more clinical data and real-world evidence become available, healthcare professionals gain confidence in the safety and efficacy of adalimumab biosimilars. This increased acceptance by physicians contributes to the broader use of biosimilars in clinical practice. Biosimilars enhance patient access to important biologic therapies, addressing unmet medical needs. Increased availability of biosimilars provides patients with additional treatment options, potentially leading to improved outcomes.

• According to the World Health Organization, chronic diseases account for approximately 74% of global deaths each year, and many involve inflammatory or autoimmune mechanisms requiring biologic treatment. The National Institutes of Health (NIH) also estimates that more than 23.5 million people in the United States suffer from autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. The increasing prevalence of these conditions significantly expands the patient base for adalimumab biosimilars used in long-term therapy.

• According to the European Commission, biosimilar medicines can reduce treatment costs by approximately 20% to 30% compared with original biologic therapies, enabling healthcare systems to treat more patients within existing budgets. The U.S. Department of Health and Human Services has also implemented biosimilar education and regulatory programs to increase competition in biologic drug markets. These policy initiatives aim to improve patient access to biologic treatments while reducing overall healthcare expenditure.

RESTRAINING FACTORS

Regulatory and Intellectual Property Challenges to Potentially Impede Market Growth

Developing biosimilars, including biosimilars, is a complex and costly process. Manufacturers need to demonstrate similarity to the reference product in terms of quality, safety, and efficacy through extensive analytical, preclinical, and clinical studies. Regulatory hurdles and legal challenges related to intellectual property can delay or hinder the market entry of biosimilars. Patent disputes and litigation may extend the time it takes for biosimilars to reach the market. Limited awareness and understanding of biosimilars among healthcare professionals, patients, and payers can slow the adoption of biosimilars. Education efforts are needed to build trust and confidence in the safety and efficacy of these products.

• According to the U.S. Food and Drug Administration, biosimilar development requires extensive analytical testing and clinical studies to demonstrate similarity to reference biologic drugs. Development programs often involve hundreds of patients in clinical trials and detailed structural analysis of biologic molecules. The World Health Organization also highlights that biosimilars must undergo strict comparability assessments to confirm safety, quality, and therapeutic effectiveness, which increases development complexity and time requirements.

• According to the European Medicines Agency, biosimilars require detailed pharmacovigilance and monitoring to ensure long-term safety. Surveys referenced by healthcare regulatory agencies indicate that nearly 30% to 40% of healthcare professionals in certain markets initially reported limited familiarity with biosimilar prescribing guidelines. Such knowledge gaps can slow adoption rates, particularly in regions where physicians remain cautious about switching patients from established biologic treatments to biosimilar alternatives.

• Download Free Sample to learn more about this report

•  

ADALIMUMAB BIOSIMILAR MARKET REGIONAL INSIGHTS

Europe to Dominate the Market due to Pioneer in Biosimilar Approvals

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East &Africa

Europe is anticipated to hold approximately 30–35% of the adalimumab biosimilar market between 2026 and 2035, Europe has been at the forefront of establishing a robust regulatory framework for adalimumab biosimilar market share. The European Medicines Agency (EMA) has been proactive in providing guidelines for the development and approval of biosimilars, including those for adalimumab. Europe has seen early approvals of biosimilars, allowing these products to enter the market sooner than in some other regions. This has contributed to a more mature and competitive biosimilar landscape. Healthcare professionals in Europe have generally shown a higher level of acceptance and confidence in prescribing biosimilars. Educational initiatives and the establishment of real-world evidence supporting the safety and efficacy of biosimilars have played a role in this acceptance.

KEY INDUSTRY PLAYERS

Key Industry Players Shaping the Market through Innovation and Market Expansion

The market is significantly influenced by key industry players that play a pivotal role in driving market dynamics and shaping consumer preferences. These key players possess extensive retail networks and online platforms, providing consumers with easy access to a wide variety of wardrobe options. Their strong global presence and brand recognition have contributed to increased consumer trust and loyalty, driving product adoption. Moreover, these industry giants continually invest in research and development, introducing innovative designs, materials, and smart features, catering to evolving consumer needs and preferences. The collective efforts of these major players significantly impact the competitive landscape and future trajectory of the market.

• Samsung Bioepis (South Korea): According to corporate information released by Samsung Bioepis, the company develops biosimilar medicines for autoimmune diseases and oncology treatments and operates research collaborations across multiple continents. The company has successfully introduced several biosimilar products in over 40 countries worldwide, supporting treatment access for large patient populations with chronic inflammatory diseases. Samsung Bioepis also maintains advanced biologics manufacturing capabilities designed to produce high-volume monoclonal antibody therapies used in conditions such as rheumatoid arthritis and Crohn’s disease.

• Boehringer Ingelheim (Germany): According to information published by Boehringer Ingelheim, the company operates in more than 130 markets worldwide and employs approximately 52,000 people globally in pharmaceutical research and manufacturing. The organization has invested heavily in biologics development, including biosimilar medicines targeting autoimmune conditions. Its biologics production facilities use advanced cell culture technologies capable of producing large-scale monoclonal antibody therapies that meet strict regulatory quality standards required for biosimilar approval.

List of Top Adalimumab Biosimilar Companies

• Samsung Bioepsis (South Korea)
• Boehringer Ingelheim (Germany)
• Sandoz (Germany)
• Zydus Cadila (India)
• Coherus Biosciences (U.S.)

INDUSTRIAL DEVELOPMENT

December, 2022: The development of biosimilars begins with extensive research and development efforts. Biosimilar developers aim to demonstrate that their product is highly similar to the reference product (Humira®) in terms of structure, function, and efficacy. This involves analytical studies, preclinical testing, and comparative clinical trials.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.